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Noroviruses are the causative agents of the majority of viral gastroenteritis outbreaks in humans. During the
past 15 years, noroviruses of genotype GGII.4 have caused four epidemic seasons of viral gastroenteritis,
during which four novel variants (termed epidemic variants) emerged and displaced the resident viruses. In
order to understand the mechanisms and biological advantages of these epidemic variants, we studied the
genetic changes in the capsid proteins of GGII.4 strains over this period. A representative sample was drawn
from 574 GGII.4 outbreak strains collected over 15 years of systematic surveillance in The Netherlands, and
capsid genes were sequenced for a total of 26 strains. The three-dimensional structure was predicted by
homology modeling, using the Norwalk virus (Hu/NoV/GGI.1/Norwalk/1968/US) capsid as a reference. The
highly significant preferential accumulation and fixation of mutations (nucleotide and amino acid) in the
protruding part of the capsid protein provided strong evidence for the occurrence of genetic drift and selection.
Although subsequent new epidemic variants differed by up to 25 amino acid mutations, consistent changes were
observed in only five positions. Phylogenetic analyses showed that each variant descended from its chronologic
predecessor, with the exception of the 2006b variant, which is more closely related to the 2002 variant than to
the 2004 variant. The consistent association between the observed genetic findings and changes in epidemiology
leads to the conclusion that population immunity plays a role in the epochal evolution of GGII.4 norovirus
strains.
Since the beginning of viral gastroenteritis outbreak surveil-
lance in the early 1990s, noroviruses have become recognized
as the major cause of reported outbreaks of acute viral gastro-
enteritis worldwide. Noroviruses form a genus within the fam-
ily Caliciviridae and are genetically and antigenically highly
variable. Currently, five distinct genogroups (GGs) are rec-
ognized. Strains belonging to GGI, GGII, and GGIV are
known to cause infections in humans. The GGs have been
subdivided further into genotypes, defined by a minimum
amino acid sequence identity over the complete capsid se-
quence of 80% (1).
The strains most commonly identified as the cause of out-
breaks belong to genotype GGII.4. In The Netherlands, this
was the case for 68% of all norovirus outbreaks that were
characterized during 12 years of surveillance and for up to 81%
of all health care-related outbreaks. Since their first detection
in The Netherlands in January 1995, the GGII.4 strains have
consistently been present in the Dutch population (46). These
observations are in agreement with those of other surveillance
studies worldwide (3, 4, 15, 17, 29, 36, 55).
During the past 15 years, four epidemic norovirus seasons
have occurred, in the winters of 1995–1996, 2002–2003, 2004–
2005, and 2006–2007. These worldwide epidemics were invari-
antly caused by the predominant genotype, GGII.4, and were
attributed to the emergence of new variant lineages of this
genotype (4, 31, 35, 52, 53). These genetic variants, which have
been identified previously by partial sequencing of either the
RNA-dependent RNA polymerase (RdRp) or the capsid gene,
have been given several names across the world. Here they are
referred to by using the first year of their detection, supple-
mented where necessary with an extra suffix. The following
variants have been identified: 1996, 1996, 2002, 2004, 2006a,
and 2006b.
The pattern of emergence of new lineages followed by large-
scale epidemics suggests that new variants obtained one or
more decisive advantages over the previously circulating pre-
dominant variant. It is unknown what the nature of this ad-
vantage is, but its basis is likely to be found in VP1, since this
protein is needed for essential properties and functions in the
viral life cycle, such as antigenicity, host specificity, host cell
binding and virus entry properties, and assembly of new par-
ticles.
Noroviruses have a positive-strand RNA genome of7.6 kb,
which is subdivided into three open reading frames (ORFs).
ORF1 encodes a polyprotein which is posttranslationally pro-
cessed into the nonstructural proteins, including the RdRp.
Conserved regions within the RdRp are commonly used as
targets for diagnostic PCR assays. At the National Institute for
Public Health and the Environment in The Netherlands
(RIVM), region A (nucleotides 4279 to 4604; Lordsdale ge-
nome numbering [GenBank accession no. X86557]) is com-
monly used for genotyping outbreak strains. The second ORF
(ORF2) encodes the major structural protein VP1. Ninety
dimers of this capsid protein form a T3 icosahedral shell
(41). In the virion, a small number of copies of the protein
encoded by ORF3 are present. The precise role of this protein
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is not clear, although it has been suggested that it functions
both in upregulation of VP1 expression and as a histone-like
protein in stabilizing the capsid-RNA complex (2, 19, 22).
The understanding of immunity against noroviruses remains
limited. Between the different GGs and genotypes, antigenic
differences as well as cross-reactivities have been demonstrated
using virus-like particles and polyclonal antisera (20). Short-
term immunity was reported, but preexisting antibodies were
not protective against reinfection with the same genotype (25,
39, 56). Studies looking at neutralizing antibodies have not
been possible due to the lack of cell culture or small-animal
model systems (13). The high level of genetic diversity be-
tween different GGs and even between genotypes within the
same GG resulting from the high mutation rate and from
recombination events contributes to a large degree of anti-
genic diversity.
Host genetic factors determining the presence or absence of
virus receptors also play an important role in susceptibility (21,
23). These receptors, the histo-blood group antigens, show
virus strain-specific binding patterns, determining the ability of
virus to infect potential host cells. Because noroviruses belong-
ing to GGII.4 have the broadest range of binding to the histo-
blood group antigens of all genotypes assayed to date, this may
explain part of the relative success of these viruses (24). Other
success factors may include a higher stability of the viral par-
ticles outside the host, a higher replication rate, or other fac-
tors that need to be investigated more thoroughly.
To obtain more insight into the genetic and structural bases
of the selective advantage of new GGII.4 variants over the old
GGII.4 variants, we determined the complete capsid se-
quences of a systematic sample of GGII.4 norovirus outbreak
strains found in The Netherlands during 13 years of surveil-
lance of viral gastroenteritis and studied their genetic diversity
and predicted structure (46). Because a high-resolution three-
dimensional (3D) model of GGII noroviruses was lacking at
the time this study was initiated, a homology model of the
capsid protein was made in silico based on the known 3D
structure of the Norwalk virus (NV; GGI.1) capsid protein.
MATERIALS AND METHODS
Strain selection. Norovirus outbreak strains for which the capsid sequence was
determined were selected from the norovirus surveillance database used at
RIVM. In this Bionumerics database (Applied Maths BVBA, Sint-Martens-
Latem, Belgium), epidemiological and virological data for all norovirus strains
found in The Netherlands since January 1994 are collected as previously de-
scribed (46). The norovirus surveillance system is a laboratory-based passive
reporting system to which municipal health services can submit patient samples
from suspected viral gastroenteritis outbreaks. Because there is mandatory re-
porting for outbreaks of illness in institutions and RIVM has been the only
laboratory providing diagnostic services for noroviruses in The Netherlands, the
collection represents a national sample of reported outbreaks.
As the first step, all GGII.4 strains detected between January 1994 and De-
cember 2004 were selected from the database. A phylogenetic tree was made
based on partial polymerase sequences of 145 nucleotides for the older se-
quences to 250 nucleotides for the strains isolated after 2001 (amplified with
primer pair JV12 and JV13 or modifications thereof [region A]) (51, 53). The
branching of the tree was used to guide the selection of outbreak strains for this
study, with at least two strains per branch selected when sufficient material was
available. Following reports of unusual outbreaks in the spring of 2006 (27, 28),
six strains from this period were included in the study. A minimum spanning tree
(MST) was made on the basis of 145 nucleotides of the polymerase gene, using
the default settings in Bionumerics, to give an overview of the distribution of
strains available in the database. An MST is a tree that connects all samples from
a database in such a manner that the summed distance between all samples or
branches is minimized. An MST is particularly useful for representing large
(genomic) data sets with relatively high similarity levels and, as such, has been
shown to enable representation of microevolution or population modeling (44,
45). Another condition is that the data set should represent the biodiversity for
the organism under study and therefore should have been gathered over a time
period that is short relative to the expected rate of change for the organism.
During tree formation, the sample with the largest number of related samples is
chosen as the root node, and subsequent branches are added in order of relat-
edness.
Viral RNA isolation, cDNA preparation, and sequencing. Stool specimens
taken in selected outbreaks were collected from the biobank. Specimens were stored
as undiluted stools at 4°C, as 10% fecal suspensions at 4°C, and as RNA extracts
frozen at80°C. Where available, extracted RNAs were used as the template. When
this failed to yield a PCR product, a new RNA extraction was done from diluted
stool or fecal samples. Sequencing of these samples was done as described previously
(11). Briefly, RNA was reverse transcribed in overlapping fragments, using avian
myeloblastosis virus reverse transcriptase (Invitrogen), and subsequently, the ob-
tained cDNA was amplified and sequenced using an ABI Prism BigDye Terminator
v3.0 ready reaction cycle sequencing kit. The primers that were used were the
following: TCTCAGATCTGAGCACGTGG (GR19A), AACAGTTAAGATTGG
GACG (GR19B), GTCTCTTGTCGAGTTCTCACG (GR20), GGTGAATTGAA
CACTACCCAGC (GR21), CTCGACCCGTGCCCACAAAGC (GR22), CATTA
TAATGCACGCCTGCGCC (GR23), GGGTCAACCAGTTCTACACAC (GR24),
CCAGCTGAAGAACCTAGTCTCG (GR25), ACGTGCCCAGGCAAGAGC
CAAT (GR-JS1), TAACATCTACTATTATATGGG (GR-JS2), TCATATTTGC
AGCAGTCCCA (GR20A), CTCTGAAGGTGCAGATGTTG (GR21A), TGTG
AATCCAGACACAGGTAG (GR24A), and ACGGGCCGCATCTGCTGT
GGAA (GR25A).
Data processing. DNA sequences were processed using SeqMan and EditSeq
(DNAStar Inc., Konstanz, Germany) and aligned and analyzed using the BioEdit
sequence alignment editor (Isis Pharmaceuticals Inc.). Alignments were done
manually or using ClustalW alignment algorithms in BioEdit. Informative sites
were determined by ProSeq 2.91. Sites were considered informative when at least
two strains had an identical amino acid mutation in the alignment. Informative
sites discriminating subsequent epidemic variants were also determined. Epi-
demic variants were defined as GGII.4 strains that were dominant for at least one
outbreak season following initial detection. Silent mutations (nucleotide muta-
tions which caused no amino acid mutation) or replacement mutations (nucle-
otide mutations which caused amino acid mutations) were determined using
ProSeq 2.91, with an insertion considered a single mutation.
Phylogenetic analyses were done in Bionumerics, using neighbor joining and
the unweighted-pair group method using average linkages, with 1,000 bootstrap
resamplings and no correction and with the gap cost set at 5%. Trees were
plotted using the program Treeview (version 1.6.6) (37) or Treecon (version
1.3b) (50), with the exception of the MST, which was calculated as well as plotted
in Bionumerics. For phylogenetic analysis of the partial polymerase and capsid
sequences, the following sequences from GenBank were included: Grimsby
strain (Hu/NoV/GGII.4/Grimsby/1995/UK; GenBank accession no. AJ004864),
Farmington Hills strain (Hu/NoV/GGII.4/Farmington Hills/2002/USA; acces-
sion no. AY502023), Hunter strain (Hu/NoV/GII.4/Hunter 284E/2004/AU [ac-
cession no. DQ078794] for the capsid and Hu/NoV/GII.4/Hunter 532D/2004/AU
[accession no. DQ078801] for the partial polymerase sequence), and Camberwell
strain (Hu/NoV/GGII.4/1994/AU [accession no. U46500] and others for the
capsid analysis).
Sequences were checked for possible recombination events by using Simplot
(version 3.2), where the window size was varied from 80 to 150, with steps of 20
nucleotides, and a distance model with Jukes-Cantor correction was used. The
capsid and RdRp sequences were analyzed independently, as well as after con-
catemerization of region A and the capsid sequences, to look for possible cross-
over in the joining region.
Homology modeling. The three-dimensional structure of the NV capsid pro-
tein (PDB code 1IHM) (40) was used as a template for homology modeling of
the GGII.4 capsid protein. Sequence alignments were made using the program
MUSCLE (14). Compared to the NV capsid protein, the GGII.4 capsid protein
has four insertions of three to seven amino acids which cannot be modeled.
Generally, such insertions are located in surface-exposed loops of proteins.
Based on the alignment of the two sequences and on the 3D structure of the NV
capsid protein, the most likely places for insertion were predicted. The GGII.4
capsid protein also has one deletion of two amino acids compared to the
NV capsid protein. The place of this deletion can be modeled and was chosen in
the same way as that for the insertions. Homology modeling was performed with
WhatIf/Yasara Twinset software (Yasara) (54).
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Nucleotide sequence accession numbers. The complete capsid nucleotide se-
quences determined in this study are accessible in the DNA DataBank of Japan
under accession numbers AB303922 through AB303941 and EF126961 through
EF126966.
RESULTS
Comparative phylogenies of the polymerase and capsid genes
and sequence analysis. A phylogenetic tree (unweighted-pair
group method using average linkages) was made to enable us
to make a representative selection of strains for capsid se-
quencing. All GGII.4 strains found in The Netherlands from
the start of viral gastroenteritis surveillance in January 1994 up
to August 2006 (n  574) for which partial polymerase se-
quences (region A) were available were included (tree not
shown). The minimum identity was 89.44%. The strains segre-
gated into three major branches, with multiple outbreak strains
per branch (n  166, 161, and 180); some smaller clusters; and
outlying strains that did not fit into any of the major groups.
The major groups were each subdivided into smaller clusters.
Strains were selected using this tree, aiming to obtain two
sequences from the largest clusters from each major group and
from five outlying strains. The total number of strains analyzed
was 26.
The MST for the partial polymerase sequences is shown in
Fig. 1. The total distance of the tree is 230 nucleotides. This
tree was not used to make the selection of the strains. How-
ever, it illustrates the grouping of the different variants and the
positioning of the selected strains because it takes into account
the localization of nucleotide changes. Strains OB2000043,
EP2002006, OB2004003, OB2004012, and OB2004039 are con-
sidered outliers based on their positions in the neighbor-join-
ing tree for all polymerase sequences (not shown).
RNA sequences of the complete capsid genes were deter-
mined and aligned (see Fig. S1 in the supplemental material).
All capsid sequences found belonged to GGII.4. The neighbor-
joining tree for the capsid sequences is shown in Fig. 2. Strains
from GenBank were included for reference. Polymerase-based
and capsid-based groupings were congruent for all strains, and
thus no intragenotypic recombination was observed. SimPlot
analysis of complete capsids as well as of complete capsids
combined with the sequences of region A revealed no potential
intergenotypic recombination sites (data not shown). The rel-
FIG. 1. MST, based on alignment of 145 nucleotides of the polymerase gene sequences (region A) of all GGII.4 strains found in The
Netherlands between January 1995 and August 2006 (n 574). Colors represent different variants, as indicated in the figure. The sizes of the circles
are drawn to scale with their member counts. The smallest circles represent 1 strain, and the largest circle (the center of the 2002 cluster) represents
70 strains. Genetic distances between the circles, in numbers of nucleotides, are given on connecting lines. The total distance is 230 nucleotides.
Strains included in this study are indicated. The strains shown as circles with dotted lines are considered outliers.
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atively high level of homology between all strains may obscure
possible recombination events, and therefore recombination
between strains belonging to the same variant of GGII.4 can-
not be ruled out.
It should be noted that three strains showed different group-
ings upon analysis of region A in the RdRp from those ob-
tained in the analysis of the capsids. Three of the five strains
that were outliers when comparing partial polymerase nucle-
otide sequences (OB2004039, OB2000043, and OB2004003)
(Fig. 1) did fit into the capsid amino acid tree and fell into their
respective variant groups (Fig. 2). Although OB2004012 clus-
tered with the 2002 variant, it was still an outlying strain.
EP2002006 was phylogenetically more similar to the eldest
strains from GenBank and was therefore used as an ancestral
strain in further analyses.
Analysis of the capsid gene and changes over time. Infor-
mative sites in the capsid sequences were then determined. An
alignment of all informative sites in the capsid is represented in
Fig. 3. Sites were considered informative when at least two
strains had an identical amino acid or nucleotide mutation in
the alignment.
At the amino acid level, 48 sites (9% of 541 amino acids)
were informative (Table 1). Thirty of these sites were located
in the P2 domain (24% of the amino acids in this domain). In
all other domains, the numbers of informative sites were sig-
nificantly lower (chi-square test; P  0.001), as follows: 3 of 40
amino acids (8%) in the N-terminal domain, 4 of 182 amino
acids (2%) in the shell domain, 10 of 184 amino acids (5%) in
the P1 domain, and 1 of 10 amino acids (10%) in the C-
terminal domain. Hypervariable sites (sites at which three or
more different amino acids were found over the 12-year pe-
riod) were found only in both protruding domains, with 13 in
P2 and 2 in P1 (Fig. 3). One amino acid insertion was observed,
at position 395, and was first detected in strains from The
Netherlands in January 2002. This insertion was located in a
highly variable loop region on top of the P2 domain.
At the nucleotide level, 267 sites were found to be informa-
tive (Table 1; see Fig. S1 in the supplemental material). The P2
domain had a higher percentage of informative mutations than
did the other domains: 24% of the nucleotide mutations in P2
were informative, 8% of those in the N-terminal domain were
informative, 13% of those in the shell domain were informa-
FIG. 2. Neighbor-joining tree for complete capsid amino acid sequences. Type strains from GenBank were used in order to emphasize and
confirm the groupings. Branch lengths are drawn to scale. Bootstrap values are percentages of 1,000 iterations.
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tive, 16% of those in the P1 domain were informative, and 20%
of those in the C-terminal region were informative. The dif-
ferences with P2 were significant for the N-terminal and shell
domains (chi-square test; P  0.01), not for the P1 and C-
terminal domains. Relatively high percentages of first- and
second-position nucleotide mutations (20% and 22%, respec-
tively) were seen for the P2 region compared to both the
percentages found for the N-terminal and shell domains taken
together (13% and 5%, respectively) and those found for the
P1 domain (19% and 5%, respectively). Of these mutations,
FIG. 3. Fixed amino acid changes (informative sites) in capsid sequences of GGII.4 outbreak strains collected between 1995 and 2006. The
informative sites throughout the protein are listed from left to right. Amino acid numbering is indicated at the top, and outbreak dates (month-year
of isolation, e.g., 01-95 is January 1995) and names are given on the left. From top to bottom, the same color indicates identical amino acids, and
different colors are distinct amino acids. Colors were assigned by frequency; amino acids that occurred most are shown in green, followed by red,
blue, and yellow (diminishing frequencies). The amino acids circled in magenta are part of the additional RGD motif present in the 2002 variant
and the earliest strain. The arrow at the top indicates where an amino acid insertion occurred. The orange bars at the bottom indicate the locations
of insertions in GGII.4 compared to NV and correspond to insertions 1 to 3 in Fig. 5A. Asterisks indicate hypervariable sites (with more than one
mutation), and the arrows below the sequences indicate the sites where an amino acid mutation occurs at each variant change (not including
2006a). Domains are indicated in the bar below the figure.
TABLE 1. Informative sites in GGII.4 capsid sequencesa
Domain
aa level nt level
aa positions
Total
length
(aa)
No. (%) of
informative
aa
nt positions
Total
length
(nt)
No. (%) of
informative
nt
No. (%) of mutations at
codon position
No. (%) of
silent
mutations
No. (%) of
replacement
mutationsFirst Second Third
N-terminal
domain
1–40 40 3 (8) 1–120 120 10 (8) 2 (20) 2 (20) 6 (60) 7 (70) 3 (30)
S 41–222 182 4 (2) 121–666 546 70 (13) 8 (11) 2 (3) 60 (86) 66 (94) 4 (6)
P1 223–276,
402–531
184 10 (5) 667–828,
1204–1593
552 91 (16) 17 (19) 5 (5) 69 (76) 75 (82) 16 (18)
P2 227–401 125 30 (24) 829–1203 375 90 (24) 18 (20) 20 (22) 52 (58) 50 (56) 40 (44)
C-terminal
domain
531–541 10 1 (10) 1593–1623 30 6 (20) 1 (17) 0 (0) 5 (83) 5 (83) 1 (17)
Total 541 48 (9) 1623 267 (16) 46 (3) 29 (2) 192 (12) 203 64
a Percentages for informative sites are given as fractions of the total domain length, in numbers of amino acids or nucleotides. Position numbers are given for GGII.4
strains. aa, amino acid(s); nt, nucleotide(s).
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44% were replacement mutations, versus 30% (3 of 10 muta-
tions) in the N-terminal domain, 6% (4 of 70 mutations) in the
shell domain, 18% (16 of 91 mutations) in the P1 domain, and
17% (1 of 6 mutations) in the C-terminal region. These differ-
ences with P2 are significant for comparisons of the P2 domain
with the shell and P1 domains or the whole capsid sequence
(chi-square test; P  0.001).
As shown in Fig. S1 in the supplemental material and in Fig.
3, changes in informative sites occurred stepwise rather than
gradually, with the steps coinciding in time with the emergence
of each respective new epidemic variant (2002, 2004, 2006a,
and 2006b). When consecutive variants were compared and
EP2002006 was considered the precursor (1996) of the 1996
variant, the numbers of stable amino acid mutations per
emerging new variant were 14 (1996 variant versus 1996
variant), 25 (1996 variant versus 2002 variant), 21 (2002 variant
versus 2004 variant), 8 (2004 variant versus 2006a variant), 25
(2004 variant versus 2006b variant), and 23 (2002 variant ver-
sus 2006b variant). Both 2006a and 2006b were compared to
the 2004 variant, since this was their temporal precursor. The
2006b variant was also compared to the 2002 variant, since
these variants are genetically more closely related based on
phylogenetic clustering (neighbor joining) (Fig. 2).
Prevalence of GGII.4 variants in The Netherlands from
January 1995 to February 2007. Since the capsid changes
showed clustering in time of GGII.4 variants and the capsid-
based variant assignment was consistent with that based on the
partial RdRp sequences used for routine surveillance, we plot-
ted the presence of the different GGII.4 variant types in The
Netherlands over time (Fig. 4). This figure shows that new
variants invariantly replaced their predecessors within 5
months of cocirculation.
Analysis of structural polymorphism of the capsid protein.
The sequence of OB2004039, a 2004 variant, was used as a
reference for modeling of the basic 3D structure of capsid
proteins used in this study. Amino acid differences in all other
strains were plotted in this 3D model. Compared to the NV
capsid protein, the GGII.4 capsid protein has four insertions,
of six, three, seven, and three amino acids, with the first three
occurring in the P2 region and the fourth occurring in the
second coding region of P1. These insertions were not modeled
because of the poor reliability of such predictions. However,
we predict that these insertions are located close together
three-dimensionally, both intra- and interdimerically. Three of
the four insertions, all located in the P2 domain, had one or
more informative sites, in contrast to the fourth insertion,
located in the P1 domain, which had none. The locations of the
insertions are shown as orange bars in Fig. 3 (note that the
fourth insertion is not shown in this figure) and as orange
arrows in Fig. 5A. In Fig. 5B, the inter- and intradimerical
interactions of one dimer pair and one-half of the neighboring
dimer are shown. In this figure, an extra RGD motif that is
present in the earliest strain as well as in the 2002 variant
strains is indicated by blue arrows. This motif is located at
amino acids 339 to 341.
Most of the informative sites mapped to the surface of the
P2 domain. Subsequent variants were compared pairwise to
identify possible informative sites that consistently changed
with every new epidemic variant. When informative sites of
ensuing variant pairs (Fig. 6A, panels i to v) were listed, five
amino acids changed between every variant pair when 2006a
was not included in the analysis (Fig. 3 and 6B). These were
amino acids 193 (D19963E20023D20043E2006b), 255 (S19963
G20023S20043G2006b), 340 (E19963G20023R20043G2006b),
407 (N19963S20023D20043S2006b), and 534 (A19963T20023
A20043T2006b).
DISCUSSION
During the past 15 years, four worldwide epidemics of acute
gastroenteritis caused by emerging variants of GGII.4 norovi-
ruses have been described. Emerging new variant lineages re-
placed the previously circulating dominant types rapidly and
completely (Fig. 4) (28, 31). The mechanisms underlying the
emergence of these new lineages as well as the biological
advantages they possessed over other circulating strains are not
yet well understood. Most biological properties that are rele-
vant for variables such as stability, assembly, antigenicity, host
FIG. 4. Graph showing the prevalence of GGII.4 variant types in The Netherlands between January 1995 and February 2007. Genotype and
variant type assignments were done based on partial polymerase sequence data (region A) available from the Dutch norovirus surveillance
database.
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cell binding, and host specificity are incorporated into the
major capsid protein of the virus. We studied the genetic vari-
ation in capsids of successive variant lineages to find possible
clues about the improved fitness of the successive emerging
variants.
In the analysis of the informative sites, for both the nucle-
otide sequences and the amino acid sequences, mutations were
fixed at a number of sites. Every successive variant had a
number of distinct, lineage-defining mutations, which were
found throughout the capsid sequence. The highest densities of
informative sites were located on the surfaces of the protruding
regions of the capsid (Fig. 3 and 5). The P2 domain had
significantly more mutations than the rest of the capsid protein
and, more specifically, many more replacement mutations
(0.11 per nucleotide, versus 0.01 to 0.03 per nucleotide for
the other domains of the capsid) (Table 1). This is clear
evidence of selective force providing new variant viruses
having certain mutations with an advantage over previously
circulating variants.
The subsequent variants of GGII.4 accumulated mutations
in chronological order, and each descended from its predeces-
sor in time, with the exception of the 2006b variant. At the
amino acid level, this variant seemed more related to the 2002
variant (Fig. 2). This newly emerging variant is likely a descen-
dant of a virus strain older than the 2004 variant that has
FIG. 5. Informative sites mapped on 3D model of GGII.4 capsid
proteins. Sites with two distinct amino acid changes over the 12-year
period are depicted in green, and sites with three or more amino acid
changes are shown in red. The conserved RGD motif is shown in blue.
(A) Dimeric subunit of two capsids, with one in gray and one in light
blue. The extra RGD motif is indicated in yellow. The locations of the
insertions compared to the NV capsid, which have not been modeled,
are indicated by orange arrows 1 to 4. The brackets on the right
indicate the different domains. The shell domain is indicated in grey,
the P1 domain is shown in green, and the P2 domain is shown in blue.
(B) Three capsid proteins, including a dimer with one-half of a neigh-
boring dimer. The gray and light blue areas form one dimer, and the
yellow capsid belongs to another dimer. The inserted RGD motif is
indicated by the blue arrows.
FIG. 6. (A) (i to v) Changes in informative sites (green) derived
from amino acid comparisons between subsequent epidemic variants.
For each comparison, two views of the capsid protein are given, with
one frontal view and one from the rear. For the 2006b variant, two
comparisons were made, with the phylogenetic precursor (2002) and
the chronologic precursor (2004). (B) Amino acids that change be-
tween every subsequent variant group, with 2006a not included.
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accumulated quite a few mutations while not causing many
outbreaks in the population.
The situation that is currently unfolding is highly intriguing.
In the spring of 2006, two distinct new variants emerged,
named 2006a and 2006b. These two new variants have been
detected and reported worldwide, often in cruise ship-related
outbreaks (27, 28). It has not been reported before that two
norovirus variants can cause epidemic-scale outbreaks simul-
taneously. The 2006a variant shows 8 amino acid mutations
compared to its predecessor, the 2004 variant, whereas the
2006b variant shows 25 amino acid mutations compared to the
2004 variant, its temporal and therefore immunologic prede-
cessor. Both 2006 variants emerged almost simultaneously
(42). It will be interesting to see if both variants continue to
cause outbreaks simultaneously in the population or if one
proves to be more successful than the other, perhaps with
differing patterns across the world.
The viral strains used for this analysis all originated from our
outbreak surveillance database. Strains that are intermediate
between the epidemic variants are likely to have reduced viral
fitness and are therefore less likely to be detected on the basis
of sampling from outbreaks. Although we did look for inter-
mediate strains bridging the different variants by choosing to
sequence a number of outliers from the polymerase alignment,
no capsid sequences that could be considered intermediates
between the different variants were found. EP2006006 does not
fit with any variant of the strains included in this study. It does,
however, show resemblance to the older strains from GenBank
that were included in the neighbor-joining tree. Since no real
intermediate strains were found, the origin of emerging vari-
ants or the reservoir in which they accumulate their defining
mutations thus remains a subject for speculation. The most
logical place is the general population. While not causing
(many) outbreaks, strains may circulate in the population and
not come to the attention of surveillance, slowly accumulating
mutations until the built-up genetic variety results in enough
antigenic variety to be able to successfully cause (more) out-
breaks and become a dominant variant. Alternatively, animal
reservoirs, a limited number of which have been recognized (7,
8, 16), or chronically infected patients (18, 34) may be places
where the virus can accumulate mutations.
Neutralizing epitopes were previously reported for the sur-
face-exposed P2 domain, and a role in antigenicity was indi-
cated for this domain in several studies with human as well as
animal caliciviruses (6, 9, 30, 32, 33, 38, 43, 48, 49).
Tan and coworkers reported the conserved RGD motif to be
involved in host cell binding (12, 47). Highly variable regions
were found in close spatial proximity to the conserved RGD
motif (Fig. 5). Tan and coworkers also reported three amino
acids, neighboring the RGD motif, which were suggested to
have a role in ligand (histo-blood group antigen) binding spec-
ificity (47). One of these surrounding amino acids, designated
IV in their paper, is an informative site in our study. Before the
2002 variant, this amino acid was Q376, and it mutated into
E376 from the 2002 variant onward. Studies are needed to
determine if these mutations lead to changes in host binding
specificities.
A second RGD motif (amino acids 339 to 341) was present
in the earliest strain sequenced as well as in the 2002 variant.
Since it was absent from variants after 2002, it does not seem
to confer a great binding advantage. The location of this motif,
in spatial proximity to the reported conserved RGD motif on
the surface of the molecule and as an insertion compared to
the NV genome, does suggest a possible role in ligand binding.
The five amino acids that were informative when comparing
all chronologic sets of variants were spread over the capsid.
One that stands out is amino acid 340 (E19963G20023R20043
G2006b), which in the 2002 variant was also part of an addi-
tional RGD motif. The functional implications of these muta-
tions remain to be determined. For our structural analyses of
the polymorphisms in the GGII.4 variants, we used a computer-
derived model of the VP1 protein. After submission of the
present study, Cao et al. published a paper on the cocrystalli-
zation of the P protein of a GGII.4 strain norovirus with its
receptor (5). No differences between our computer model and
this high-resolution structure were found to be of influence to
the data presented here.
One could speculate that the location and positioning of the
P2 domain of the capsid might explain part of the great prev-
alence of mutations in this area. The protruding region is
connected to the shell domain with a hinge region, and an
additional point of flexibility between P1 and P2 was reported
(10, 40). This provides flexibility to slightly adjust to the posi-
tion of the protruding region on top of the shell domain if
needed, thus allowing for more conformational changes and
thus for more mutations in this region than in the rest of the
protein (10). This does not explain the epidemiological obser-
vations, however, and therefore we do not think it is the com-
plete story.
Similarly, a possible advantage that new lineages of GGII.4
might have obtained by the accumulation of mutations is in-
creased stability. However, even though increased stability of
the viral particles outside the host would increase the number
of infectious particles of the more stable variant available for
infection, it does not explain the rapid and complete replace-
ment of previous variants that circulated in the population
(31). Improved binding or a broadened host range also does
not provide a tight explanation for the replacement of previ-
ously circulating strains.
The most likely advantage for new variants over older ones
is that of immune evasion. Noroviruses, particularly strains of
GGII.4, are highly prevalent in the population. During epi-
demic seasons, up to 86% of norovirus outbreaks were caused
by the predominant genotype, GGII.4, followed by a sharp
drop in the prevalence of this genotype in the subsequent
season (46). Then, only after the emergence of a genetically
distinct new lineage of this genotype, the prevalence of GGII.4
strains rose again to cause a new epidemic.
A similar pattern of so-called epochal evolution has been
described very elegantly for influenza A virus (H3N2) (26),
where periods of phenotypic stasis are separated by the step-
wise emergence of phenotypically distinct new variants, as we
also see here for noroviruses. During the periods of phenotypic
(and antigenetic) stasis, neutral or almost neutral mutations do
occur and accumulate if they are beneficial or at least not
disadvantageous. For influenza virus, this pattern of evolution
and emergence of genetically novel variants is attributed to
host population immunity and subsequent antigenic escape by
the virus. The striking parallel observed here for norovirus
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suggests that this pattern of epidemics is driven by (popula-
tion) immunity as well.
No long-term immunity to norovirus infection has been re-
ported so far. Short-term protective antibodies have been re-
ported, however, and repeated exposure, which is likely to
occur with the high prevalence of norovirus, will lengthen the
duration of specific protection. Studies with NV in volunteers
suggested that immune protection wanes after 6 months with-
out reexposure (25, 39).
In agreement with the hypothesis that immunity to the pre-
dominant GGII.4 variant built up in the population, Nilsson
and coworkers reported on the in vivo evolution of a GGII.3
strain infecting a chronically ill immunocompromised patient
(34). They observed the accumulation of amino acid mutations
in the capsid protein and suggested that these changes gave
rise to a new phenotype, through immune response-driven
evolution. Similar to our findings, they found most amino acid
mutations in the P2 domain of the capsid. This observation
supports the idea that new variants may possibly emerge from
chronically infected patients.
The data presented in this paper underpin observations that
the elevated numbers of norovirus outbreaks in the winter
seasons of 1995–1996, 2002–2003, 2004–2005, and 2006–2007
(4, 31, 46, 53) were mainly, if not solely, due to the emergence
of new variants of the GGII.4 genotype. The gradual increase
in nucleotide mutations in the sequences of norovirus GGII.4
strains confirms that genetic drift occurs in the virus. Addition-
ally, the stepwise fixation of numbers of amino acid mutations
in the capsid of this predominant genotype, mainly in the
surface-exposed P2 domain, is likely to be caused by selective
pressure due to population immunity, which resulted in emerg-
ing variants which have caused worldwide epidemic rises in
outbreak numbers.
Further immunological studies of this variation in the capsid
protein are urgently needed to shed light on the mechanisms of
immune evasion utilized by the most prevalent genotype of
norovirus.
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